Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated.
Stevens AM, Schafer ES, Li M, Terrell M, Rashid R, Paek H, Bernhardt MB, Weisnicht A, Smith WT, Keogh NJ, Alozie MC, Oviedo HH, Gonzalez AK, Ilangovan T, Mangubat-Medina A, Wang H, Jo E, Rabik CA, Bocchini C, Hilsenbeck S, Ball ZT, Cooper TM, Redell MS. Stevens AM, et al. Cancers (Basel). 2023 Feb 20;15(4):1344. doi: 10.3390/cancers15041344. Cancers (Basel). 2023. PMID: 36831684 Free PMC article.
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
Stevens AM, Xiang M, Heppler LN, Tošić I, Jiang K, Munoz JO, Gaikwad AS, Horton TM, Long X, Narayanan P, Seashore EL, Terrell MC, Rashid R, Krueger MJ, Mangubat-Medina AE, Ball ZT, Sumazin P, Walker SR, Hamada Y, Oyadomari S, Redell MS, Frank DA. Stevens AM, et al. Blood Adv. 2019 Dec 23;3(24):4215-4227. doi: 10.1182/bloodadvances.2019000499. Blood Adv. 2019. PMID: 31856268 Free PMC article.
Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia.
Narayanan P, Man TK, Gerbing RB, Ries R, Stevens AM, Wang YC, Long X, Gamis AS, Cooper T, Meshinchi S, Alonzo TA, Redell MS. Narayanan P, et al. Among authors: stevens am. Clin Transl Oncol. 2021 Oct;23(10):2141-2154. doi: 10.1007/s12094-021-02621-w. Epub 2021 May 4. Clin Transl Oncol. 2021. PMID: 33948920 Free PMC article.
Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.
Perez MW, Sias-Garcia O, Daramola A, Wei H, Terrell M, Rashid R, Park WD, Duong K, Horton TM, Li F, Cherayil N, Koren JV, Gant VU, Junco JJ, Curry CV, Stevens AM, Lin CY, Yi JS. Perez MW, et al. Among authors: stevens am. Blood Adv. 2021 Dec 14;5(23):4864-4876. doi: 10.1182/bloodadvances.2020003737. Blood Adv. 2021. PMID: 34543389 Free PMC article.
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Schafer ES, et al. Among authors: stevens am. Pediatr Blood Cancer. 2022 Oct;69(10):e29812. doi: 10.1002/pbc.29812. Epub 2022 Jun 21. Pediatr Blood Cancer. 2022. PMID: 35726868 Clinical Trial.
259 results